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GPR120: A bi-potential mediator 
to modulate the osteogenic and 
adipogenic differentiation of 
BMMSCs
Bo Gao1,*, Qiang Huang2,*, Qiang Jie1,*, Wei-Guang Lu1,*, Long Wang1, Xiao-Jie Li1, 
Zhen Sun1, Ya-Qian Hu1, Li Chen3, Bao-Hua Liu4, Jian Liu1, Liu Yang1 & Zhuo-Jing Luo1
Free fatty acids display diverse effects as signalling molecules through GPCRs in addition to their 
involvement in cellular metabolism. GPR120, a G protein-coupled receptor for long-chain unsaturated 
fatty acids, has been reported to mediate adipogenesis in lipid metabolism. However, whether 
GPR120 also mediates osteogenesis and regulates BMMSCs remain unclear. In this study, we showed 
that GPR120 targeted the bi-potential differentiation of BMMSCs in a ligand dose-dependent manner. 
High concentrations of TUG-891 (a highly selective agonist of GPR120) promoted osteogenesis via 
the Ras-ERK1/2 cascade, while low concentrations elevated P38 and increased adipogenesis. The fine 
molecular regulation of GPR120 was implemented by up-regulating different integrin subunits (α1, 
α2 and β1; α5 and β3). The administration of high doses of TUG-891 rescued oestrogen-deficient 
bone loss in vivo, further supporting an essential role of GPR120 in bone metabolism. Our findings, 
for the first time, showed that GPR120-mediated cellular signalling determines the bi-potential 
differentiation of BMMSCs in a dose-dependent manner. Additionally, the induction of different 
integrin subunits was involved in the cytoplasmic regulation of a seesaw-like balance between ERK 
and p38 phosphorylation. These findings provide new hope for developing novel remedies to treat 
osteoporosis by adjusting the GPR120-mediated differentiation balance of BMMSCs.
Osteoporosis (OP) is characterized by a decrease in bone mass and density accompanied by a dramatic 
change in the osteoblast/adipocyte ratio in the bone marrow cavity1,2. The abnormal osteoblast/adipo-
cyte ratio is determined by the imbalance between the decreased osteogenic and increased adipogenic 
differentiation tendency of bone marrow mesenchymal stem cells (BMMSCs)3, and this imbalance will 
cause more fat to reside in the bone marrow cavity, which in turn modulates the bone formation process, 
ultimately causing osteoporosis4. Many core factors, such as β -catenin, Runx2 and Ppar-γ , are highly 
involved in the bi-potential differentiation process of BMMSCs5–7; however, little evidence has shown 
how BMMSCs sense the extracellular signals and change their differentiation tendency in the first place.
Free fatty acids (FFAs) display diverse effects as signalling molecules through a few G protein-coupled 
receptors (GPCRs) in addition to their involvement in cellular metabolism. Ligands bind specifically to 
GPCRs to stimulate and induce various cellular responses via several second messenger pathways—e.g., 
modulation of cAMP production, the phospholipase C pathway, Ca2+ channels, and mitogen-activated 
protein kinases8–10.
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In recent decades, GPR40 and GPR120, which have been shown to be activated by FFAs, were 
reported to be expressed in bone-related cells11–13. Wauquier et al. and Gao et al. reported that GPR40 
was expressed in osteoclasts, osteocytes and BMMSCs and protected bone loss via the inhibition of oste-
oclast differentiation and mediated oestrogen-induced osteogenesis of BMMSCs11,14,15.
GPR120, a G protein-coupled receptor for long-chain unsaturated fatty acids, has been reported to 
mediate adipogenesis and glucagon-like peptide-1 secretion in lipid metabolism16. GPR120 was also 
found to be involved in the differentiation regulation of macrophagy and chondrocytes17,18. Moreover, 
GPR120 was the specific membrane receptor of ω-3 PUFA (DHA and EPA), which was reported to accel-
erate osteoblast differentiation and proliferation19–22. Additionally, in our recent study, we showed that 
GPR120 mediated Ginsenoside-Rb2-induced proliferation and the anti-apoptosis effects of BMMSCs23, 
also suggesting a possible role of GPR120 in bone metabolism. However, whether GPR120 directly senses 
extracellular signals and mediates osteoblast differentiation and the fine regulation of BMMSCs by FFAs 
remain unclear.
Tsujimoto and San-Gun Roh’s study showed that GPR120 mediated the differentiation and maturation 
of adipocytes both in vivo and in vitro24,25. Therefore, we speculated that GPR120 might be the “button” 
to modulate osteogenesis as well as GPR120-mediated adipogenesis of BMMSCs, and these two events 
might be underway through different molecular mechanisms.
Our results, for the first time, demonstrated that, in vitro, ligand dosage-dependent GPR120 is a 
bi-potential mediator to modulate the osteogenic and adipogenic differentiation process of BMMSCs by 
activating different integrin families, such as integrin α 1β 1, integrin α 2β 1 and integrin α vβ 3. In vivo, 
we found that the injection of the agonist of GPR120 into the bone marrow cavity significantly reversed 
the process of bone loss. These findings indicated that GPR120, currently a target for the treatment of 
type 2 diabetes26–28, and the newly found “obesity gene” that forecasts obesity, could have bonus effects 
on the prevention of osteoporosis and obesity in the future.
Results
GPR120 positively regulates the osteogenesis of BMMSCs. First, we detected the expression of 
GPR120 transcripts in primary BMMSCs and found that the expression level of GPR120 was gradually 
increased during osteogenic induction. Moreover, the level of GPR120 protein after 14 and 21 days of 
induction was much higher than that after 3 and 7 days of induction (Fig. 1A,B), suggesting a possible 
role of GPR120 in the osteoblast differentiation of BMMSCs.
To further explore the role of GPR120 in osteogenesis, GPR120 was knocked down in BMMSCs using 
stable shRNA interference. Immunostaining, western blotting and RT-PCR showed that the expression 
of GPR120 was significantly reduced to an extremely low level (Fig. 1C–E). The potential of osteoblast 
differentiation of these BMMSCs was evaluated by ALP and Alizarin Red staining in the presence or 
absence of 50 μ M TUG-891, which is a highly selective agonist of GPR12029. Statistical analyses of both 
ALP and Alizarin Red staining showed that the knock-down of GPR120 weakened the osteogenesis of 
BMMSCs dramatically; however, in the presence of 50 μ M TUG-891, the ability of osteogenesis was 
not altered (Fig.  2A–D). These results showed that GPR120 mediated the osteogenic differentiation of 
BMMSCs, at least partially. These data were further confirmed by comparing the expression of osteogenic 
markers. Alp, Runx2 and Ocn were significantly down-regulated when GPR120 was knocked down, and 
TUG-891 did not rescue this effect (Fig. 2E).
GPR120 promotes the osteogenesis of BMMSCs via the Ras-ERK1/2 signalling pathway. 
To elucidate the underlying mechanism of GPR120 in osteoblast differentiation, the expression level 
of phosphate ERK1/2 (pERK1/2) and total ERK1/2, AKT, PI3K and JNK were compared in the 
osteogenesis-induced primary BMMSCs. The western blotting results showed that pERK1/2 was obvi-
ously increased when GPR120 was activated by TUG-891 and was significantly reduced when GPR120 
was knocked down. However, the expression levels of total ERK1/2, AKT, PI3K and JNK were not sig-
nificantly changed by the stimulus (Fig. 3A).
To further confirm that the phosphorylation and activation of the ERK1/2 pathway were essential 
for the GPR120-mediated osteoblast differentiation of BMMSCs, U0126, an inhibitor of the ERK1/2 
pathway, was used. Primary BMMSCs were cultured in osteogenic medium in the presence of 50 μ M 
TUG-891 and/or 10 μ M U0126. The results of ALP and Alizarin Red staining showed that U0126 could 
significantly block the osteogenic induction effect of TUG-891 (Fig. 3B–E). Moreover, the expression of 
osteogenic markers Alp, Runx2 and Ocn was significantly reduced in the presence of U0126 (Fig. 3F). To 
further uncover the upstream regulator of ERK1/2 in the osteogenic induction of BMMSCs, we tested 
the Ras kinase activity. Figure  3G showed that the activation of GPR120 elevated the expression level 
of Ras-GRF, which is the active form of Ras, while the knockdown of GPR120 dramatically reduced 
the levels of Ras-GRF, further indicating that GPR120 might promote the osteogenic differentiation of 
BMMSCs via the Ras-ERK1/2 signalling pathway.
The GPR120 effects on osteogenesis are exerted in a ligand dose-dependent manner. 
Tsujimoto and colleagues showed that GPR120-deficient mice that were fed a high-fat diet developed 
obesity, glucose intolerance and fatty liver with decreased adipocyte differentiation and lipogenesis25. 
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This discrepancy of GPR120 in adipocyte differentiation and osteoblast differentiation led us to further 
study the bi-potential differentiation of BMMSCs with the activation of GPR120 in vitro and in vivo.
TUG-891 is a highly selective agonist of GPR120 compared with other agonists30. We added TUG-
891 in increasing concentrations from 0 to 100 μ M (0, 0.1, 0.5, 1, 5, 10, 30, 50, 100 μ M) to the osteo-
genic medium for 14 days. The results showed that high concentrations of TUG-891 (30, 50, 100 μ M) 
markedly increased ALP staining and the mineralized matrix area compared with low concentrations 
of TUG-891 (0.1, 0.5, 1 μ M) and control cells (P < 0.05, Fig. 4A–D). High concentrations of TUG-891 
(30, 50, 100 μ M) also significantly improved the expression level of osteogenic gene markers, while there 
were no significant changes in cells cultured with low concentrations (0.1, 1, 5 μ M) (P < 0.05, Fig. 4E). 
Additionally, 0.5 μ M TUG-891 significantly weakened the osteogenic ability of BMMSCs, indicating that 
a low concentration of TUG-891 might have a reverse effect to interfere with the osteogenic process. 
Furthermore, 0.5 μ M TUG-891 reduced the expression of Alp but not that of Runx2 and Ocn (P < 0.05, 
Fig. 4E).
The western blotting results showed that high concentrations of TUG-891 (30, 50 and 100 μ M) mark-
edly activated Ras-GRF and ERK1/2 phosphorylation, while total Ras and ERK1/2 did not obviously 
change (Fig.  4F). Low concentrations of TUG-891 (0.1, 0.5 and 1 μ M) were found to not activate the 
Ras pathway but downregulated the phosphorylation of ERK1/2, suggesting that there might be another 
Figure 1. GPR120 positively regulates the osteogenesis of BMMSCs. BMMSCs were cultured for 0, 
3, 7, 14 and 21 days of osteogenesis, respectively. (A) RT-PCR and (B) western blot analysis of GPR120. 
BMMSCs were invalidated for GPR120 expression or transfected with a nontargeting vector. (C) 
Immunocytochemistry shows the expression of GPR120 (red) by BMMSCs. The merged image shows 
GPR120 with DAPI nuclear staining. (D) RT-PCR and (E) western blot analysis of GPR120. The expression 
of each target gene was calculated as the relative expression to β -actin and is represented as normalized fold 
expression. Data are represented as the mean ± SD of 3 independent experiments. *P < 0.05 and **P < 0.01 
compared with the control group.
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molecule participating in the inhibition of pERK1/2 in the presence of low concentrations of TUG-891 
(Fig. 4F).
A study by Olsen and Volloch indicated that p38 could repress the phosphorylation of ERK and sub-
sequently promote adipogenesis while inhibiting osteogenesis31. Therefore, p38, a key negative regulator 
of ERK, was detected during the osteoblast differentiation of BMMSCs with a sequential concentration 
of TUG-891. We found that the phosphorylation of p38 was up-regulated in the presence of low concen-
trations of TUG-891 (0.1, 0.5 μ M). However, p38 phosphorylation was down-regulated in the presence 
of high TUG-891 concentrations (Fig. 4F), indicating that a low concentration of TUG891, an agonist of 
GPR120, might inhibit osteoblast differentiation through p38-mediated inhibition of the ERK pathway.
Low concentrations of TUG-891 play a positive role in inducing the adipogenesis of 
BMMSCs. To figure out why low concentrations of TUG-891 weaken the osteogenesis of BMMSCs, 
cells underwent adipocyte differentiation in adipogenic medium with different concentrations [0 (Con), 
0.1, 0.5, 1, 5 μ M] of TUG-891 for 3 days. Interestingly, we found that 0.5 μ M TUG-891 significantly 
increased the ability of adipogenesis, while 5 μ M TUG-891 markedly reduced the adipogenic potential 
compared with controls observed by oil red staining and lipid quantification (Fig. 5A,B, P < 0.05). RT-PCR 
showed that low concentrations of TUG-891, particularly 0.5 μ M, significantly increased the expression 
level of Ppar-γ and Fabp4 (Fig. 5C, P < 0.05), indicating that low concentrations of TUG-891 played an 
essential role in adipogenic differentiation rather than the osteogenic differentiation of BMMSCs and, 
most importantly, that GPR120 participated in bone metabolism in a ligand dosage-dependent manner.
To clarify the underlying mechanism of the adipogenic-inducing effect of low concentrations of TUG-
891, the Ras-ERK1/2 pathway was evaluated by western blotting. Consistent with the findings regarding 
the osteoblast differentiation of BMMSCs, the results showed that low concentrations of TUG-891, par-
ticularly 0.1 and 0.5 μ M, markedly down-regulated the expression level of pERK1/2 (Fig. 5D). Next, we 
further tested whether Ras and Ras-GRF could be modulated by low concentrations of TUG-891 under 
adipogenic conditions. However, the results showed no difference between each group, indicating that a 
low dose of TUG-891 might inactivate ERK1/2 through other mechanisms (Fig. 5D). We then tested the 
Figure 2. Lack of GPR120 negatively impacts the osteogenesis of BMMSCs. Control and GPR120 shRNA 
BMMSCs were incubated for 14 days of osteogenesis in the presence or absence of 50 μ M TUG-891. (A) 
ALP (scale bar = 200 μ m) and (B) Alizarin red (scale bar = 80 μ m) staining of cells. (C) Difference in 
the ALP activity of osteogenic differentiation. The control value for ALP activity was 0.415 ± 0.020 units/
mg protein. (D) Difference in the mineralization of osteogenic differentiation. The control value for 
mineralization was 0.910 ± 0.013 OD. (E) Difference in the osteogenic mRNA expression of Alp, Runx2 
and Ocn. The expression of each target gene was calculated as the relative expression to β -actin and is 
represented as normalized fold expression. Data are represented as the mean ± SD of 3 independent 
experiments. *P < 0.05 and **P < 0.01 compared with the control group.
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expression of phosphorylated p38, and the results showed that low doses of TUG-891, particularly 0.1 
and 0.5 μ M, up-regulated the expression of pp38, which might consequently inactivate ERK phosphoryl-
ation to induce the adipogenesis of BMMSCs (Fig. 5D).
GPR120 activates different integrin subunits to modulate osteogenesis or adipogenesis in 
a ligand dose-dependent manner. To further determine why GPR120 could be the bi-potential 
mediator to modulate either the osteogenesis or adipogenesis of BMMSCs and how GPR120 could acti-
vate ERK and p38 in a ligand dose-dependent manner, the expression of integrin family members was 
tested by western blotting. In BMMSCs that underwent 14 days of osteogenesis or 3 days of adipogen-
esis, we found that a high concentration of TUG-891 (50 μ M) up-regulated integrin α 1, α 2, and β 1 but 
down-regulated integrin α V and β 3 compared with the control group (0 μ M TUG-891). By contrast, 
a low concentration of TUG-891 (0.5 μ M) down-regulated integrin α 1, α 2, and β 1 but up-regulated 
integrin α V and β 3 (Fig. 6A).
To exclude the possibility that TUG-891 directly activated integrin family members, but not through 
GPR120, we used GPR120-knocked down BMMSCs and subjected cells to 14 days of osteogenesis and 
3 days of adipogenesis with a low and high concentration of TUG891, and then, integrin expression was 
Figure 3. GPR120 promotes the osteogenesis of BMMSCs via the Ras-Erk1/2 cascade. (A) Western 
blotting analysis of ERK1/2, pERK1/2, Akt, PI3K and JNK. Con: Control cells, Con + T: Control cells 
incubated with 50 μ M TUG-891, shRNA: GPR120 shRNA cells (B) ALP (scale bar = 200 μ m) and (C) 
Alizarin red staining (scale bar = 80 μ m) of cells. (D) ALP activity of osteogenic differentiation between 
Con + T and Con + T + U BMMSCs. The control value for ALP activity was 0.720 ± 0.015 units/mg protein. 
(E) Mineralization of the osteogenic differentiation between Con + T and Con + T + U BMMSCs. The 
control value for mineralization was 0.985 ± 0.012 OD. Con + T: Control cells incubated with 50 μ M TUG-
891, Con + T + U: Control cells incubated with 50 μ M TUG-891 plus10 μ M U0126. (F) Osteogenic mRNA 
expression of Alp, Runx2 and Ocn. (G) Western blotting analysis of Ras and Ras-GRF. The expression of 
each target gene was calculated as the relative expression to β -actin and is represented as the normalized 
fold expression. Data are represented as the mean ± SD of 3 independent experiments. *P < 0.05 and 
**P < 0.01 compared with the Con + T group.
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tested by western blotting. Figure 6B showed that neither a high concentration nor a low concentration of 
TUG-891 affected the expression of integrin family members in GPR120-knocked down BMMSCs, indi-
cating that the activation of different integrin receptors by dose-dependent TUG-891 occurred through 
GPR120.
Olsen and Volloch indicated in their study that ERK could be activated by integrin α 1β 1 and α 2β 1 
to promote osteogenesis, while p38 could be activated by integrin α Vβ 3 to repress ERK and induce 
adipogenesis31. The molecular mechanisms of high and low concentrations of TUG-891 targeting both 
the osteogenesis and adipogenesis of BMMSCs through GPR120 are depicted in schematic diagram 
(Fig. 6C).
GPR120 improves the bone mass and bone structure of ovariectomized mice. To further 
evaluate the effect of GPR120 on bone mass and micro-architecture in vivo, different concentrations of 
TUG-891 and vehicle were injected into the proximal femur of ovariectomized (OVX) mice. To avoid 
the indirect impact of hypodermic injection on bone mass and density, a local direct injection to the 
bone marrow cavity was adopted in this study. The detailed time course of the in vivo administration 
of TUG-891 is shown in Fig. 7D. When all of the mice were collected at 10 weeks after operation, there 
were no significant differences in the body weights among all of the groups. The analyses of the trabec-
ular bone of the distal femur showed that ovariectomy reduced the bone mass and deteriorated bone 
micro-architecture (Fig. 7A,B), as indicated by the decrease in BMD, Conn.D, Tb.N, Tb.Th and BV/TV 
in OVX mice (Fig. 7E–K, P < 0.05). However, SMI and Tb.Sp were increased (P < 0.05). The treatment 
of ovariectomized mice with 10, 30 and 50 μ mol/kg of TUG-891 in part rescued these bone parameters 
Figure 4. TUG-891, an agonist of GPR120, significantly promotes the osteogenesis of BMMSCs at 
high concentrations. BMMSCs were incubated for 14 days of osteogenesis in the presence of different 
concentrations of TUG-891 [0 (Con), 0.1, 0.5, 1, 5, 10, 30, 50, 100 μ M]. (A) ALP (scale bar = 200 μ m) 
and (B) Alizarin red (scale bar = 80 μ m) staining of cells. (C) Effect of TUG-891 on the ALP activity of 
the osteogenic differentiation of BMMSCs. The control value for ALP activity was 0.432 ± 0.015 units/
mg protein. (D) Effect of TUG-891 on the mineralization of the osteogenic differentiation of BMMSCs. 
The control value for mineralization was 0.920 ± 0.016 OD. (E) Effect of TUG-891 on the osteogenic 
mRNA expression of Alp, Runx2 and Ocn. (F) Western blot analysis of ERK1/2, pErk1/2, Ras, Ras-GRF, 
p38 and pp38. The expression of each target gene was calculated as the relative expression to β -actin and 
is represented as normalized fold expression. Data are represented as the mean ± SD of 3 independent 
experiments. *P < 0.05 and **P < 0.01 compared with the control group.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:14080 | DOi: 10.1038/srep14080
and improved the micro-architecture of the trabecular bone in the distal femur (Fig. 7A,B). Moreover, we 
evaluated the changes in bone micro-architecture by VG staining. As shown in Fig. 7C, compared with 
the sham-operated group, the number of trabeculae decreased and the trabecular space became broader 
in the OVX group. High concentrations of TUG-891 (10, 30, and 50 μ mol/kg) reversed these changes 
by an elevated number of trabecular bone and a reduction of trabecular bone space, while there were 
no changes in the concentration groups of 0.1 and 1 μ mol/kg. To determine whether the activation of 
GPR120 could influence the bone formation rate (BFR) of bone in vivo, fluorochrome double labelling 
was performed by intramuscular injection of tetracycline hydrochloride and calcein administered 12 and 
2 days before sacrifice. In all groups, the fresh osteoids were labelled with tetracycline hydrochloride and 
calcein (Fig. 8A). As shown in Fig. 8B, the OVX group demonstrated a significant decrease (P < 0.05) in 
BFR in contrast to the sham-operated group. However, the BFR of the groups treated with high concen-
trations of TUG-891 (10, 30, 50 μ mol/kg) exhibited a significant increase compared with the OVX group 
(P < 0.05). Our research demonstrated that high concentrations of TUG-891 could protect the trabecular 
bone mass via increasing BFR.
Discussion
The link between bone and fat has been studied for many years, and the role of FFAs, as important 
lipids in lipid metabolism, in bone metabolic diseases, such as osteoporosis, has been attracting much 
attention32. Understanding the role and underlying mechanism of FFA in affecting skeletal cells will 
undoubtedly help us to further understand the relationship between fat and bone and explore more 
efficient anti-osteoporosis drugs.
Figure 5. Low concentrations of TUG-891 induce the adipogenesis of BMMSCs. BMMSCs were 
incubated for 3 days of adipogenesis in the presence of different concentrations of TUG-891 [0 (Con), 0.1, 
0.5, 1, and 5 μ M]. (A) Effect of low concentrations of TUG-891 on oil red staining (scale bar = 40 μ m) and 
(B) quantification of lipid numbers of adipogenic differentiation in BMMSCs; the lipid quantification of 
each group was carried out using the method described in the Materials and Methods section. (C) Effect of 
low concentrations of TUG-891 on the adipogenic mRNA expression of Pparγ and Fabp4. (D) Western blot 
analysis of Erk1/2, pErk1/2, Ras, Ras-GRF, p38 and pp38. The expression of each target gene was calculated 
as the relative expression to β -actin and is represented as normalized fold expression. Data are represented 
as the mean ± SD of 3 independent experiments. *P < 0.05 and **P < 0.01 compared with the control group.
www.nature.com/scientificreports/
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The best way to prevent osteoporosis in the aging population is to build strong bones in early life 
through consuming a well-balanced diet (e.g., calcium and ω-6 and ω-3 fatty acids) and following a 
routine exercise program33. Although direct evidence for the beneficial effect of dietary ω-3 fatty acids 
on human osteoporosis is still lacking, experiments using animal and cell culture models have indicated 
promising applications of ω-3 PUFA in this disease20. Hogstrom et al. also reported that the serum phos-
pholipid levels of ω-3 PUFA and DHA were positively related to bone mass density (BMD)22. Moreover, 
there was an available study demonstrating that the tissue levels of ω-3 PUFA were positively correlated 
with bone mass in postmenopausal women34. However, another unsaturated fatty-acid, ω -6 PUFA, was 
reported to play a negative role in bone formation35–38. Both ω-3 PUFA and ω -6 PUFA exerted their 
function through GPR120. However, it is unknown why GPR120 was able to mediate a different biolog-
ical process with a different ligand.
GPR120, as a G protein-coupled receptor, has been reported to accelerate adipocyte differentia-
tion and modulate the secretion of insulin and glycometabolism16. Whether GPR120 mediates the 
osteogenesis-induction effect in vivo and in vitro remains unclear. In this study, we found that the expres-
sion level of GPR120 increased with the induction of osteogenesis in BMMSCs. Next, we knocked down 
GPR120 in BMMSCs, which showed markedly reduced osteogenesis. Moreover, this effect was modu-
lated by the Ras-ERK1/2 cascade, a finding that was consistent with the results from Katsuma et al. that 
the extracellular signal-regulated kinase (ERK) pathway worked downstream of GPR120 to modulate 
biologic functions39.
The effect of GPR120 on bone metabolism occurred in a ligand dose-dependent manner. High 
concentrations of TUG-891 significantly promoted osteogenesis via the Ras-ERK1/2 cascade, while 
low concentrations increased the adipogenesis of BMMSCs by elevating p38 in vitro. Our finding of a 
dosage-dependent effect of the agonist of GPR120 in this study might better explain the different roles 
of GPR120 in both osteogenesis and adipogenesis in the presence of different ligands. Such situations 
exist in the physiological process in vivo. Along with maturation and aging, the levels of ω-3 PUFA and 
other “osteo-inductive” FFAs in the body were gradually reduced and the relatively “adipo-inductive” 
FFAs were elevated. The minute difference among ligand-dependent GPR120 functions and/or the slight 
affinity difference of the ligands might modulate the biological process and cell fate of BMMSCs. Our 
Figure 6. GPR120 activates different integrin family members to modulate osteogenesis or adipogenesis 
in a ligand dose-dependent manner. BMMSCs were incubated for 14 days of osteogenesis or 3 days of 
adipogenesis in the presence of different concentrations of TUG-891 (0, 0.5, 50 μ M). (A) Western-blot 
analysis of integrin α 1, α 2, α V, β 1 and β 3 of control BMMSCs. (B) Western-blot analysis of integrin 
α 1, α 2, α V, β 1 and β 3 of GPR120 knocked-down BMMSCs. (C) Molecular mode of GPR120 targeting 
the osteogenesis and adipogenesis of BMMSCs. Arrows indicate to activate the target. The repression 
symbol indicates the inhibition of the target. The green and blue arrows indicate the pathway of the high 
concentration and low concentration of TUG-891, respectively, targeting GPR120 and their downstream 
targets.
www.nature.com/scientificreports/
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findings, for the first time, elucidated the molecular mechanism of osteoblast and adipocyte differentia-
tion mediated by different ligands acting on the same receptor, and GPR120 was demonstrated to be the 
key molecule between the osteo- and adipo-differentiation of BMMSCs.
However, the cytoplasmic switch downstream of ligand dose-dependent GPR120 in cell fate determi-
nation remains unclear. Integrin family members are the principal mediators of the molecular dialogue 
between cells and their extracellular matrix (ECM) environment40–42. Previous studies revealed that α V, 
α 5β 1, α vβ 3, and β 3/β 5 integrins are involved in the interaction between osteoblasts and the ECM and 
affect osteoblast function and bone remodelling43–45. Moreover, many studies have indicated that the 
engagement of α 1β 1 and α 2β 1 binding sites markedly activates ERK and activates p38 kinase rather 
weakly46,47. The more α 1β 1 and α 2β 1 sites that are engaged, the higher are the levels of activated ERK, 
while the engagement of α vβ 3 binding sites strongly activates p38 kinase and rather weakly activates 
ERK48–51. Olsen and Volloch indicated that α 1β 1 and α 2β 1 could activate Ras-Erk to induce osteogen-
esis, while integrin α Vβ 3 could activate p38 and subsequently repress the phosphorylation of ERK to 
promote adipogenesis31. Our team also reported that hBMSCs obtained from senile osteoporotic patients 
Figure 7. GPR120 improves the bone mass and bone structure of ovariectomized mice. Groups: a: 
Sham; b: OVX; c: OVX + TUG-891 (0.1 mg/kg); d: OVX + TUG-891 (1 mg/kg); e: OVX + TUG-891 (5 mg/
kg); f: OVX + TUG-891 (10 mg/kg); g: OVX + TUG-891 (30 mg/kg); h: OVX + TUG-891 (50 mg/kg). (A,B) 
Analysis of micro-CT in the distal metaphyseal femur region. (C) Van Gieson (VG) staining of the distal 
femur. The figure was 40 × and 100 × of the original section. (D) Procedure for the in vivo injection of TUG-
891 among the different groups. (E,K) Analysis of micro-CT quantification in the distal metaphyseal femur 
region. The following 3D indices in the defined region of interest (ROI) were analysed: BMD, Conn.D, SMI, 
Tb.N, Tb.Th, Tb.Sp and BV/TV. *P < 0.05 and **P < 0.01 compared with the sham group. #P < 0.05 and 
##P < 0.01 compared with the OVX group.
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gradually lose their osteogenic capability through the abnormal regulation of the integrin α 2-ERK-Runx2 
signalling pathway. In this study, we showed that high concentrations of TUG-891 from 30 to 100 μ M 
markedly induced the osteogenesis of BMMSCs through the activation of GPR120-integrin α 1β 1 via 
the α 2β 1-Ras-ERK1/2 signalling pathway. Moreover, low concentrations of TUG-891, from 0.1 to 1 μ M, 
promote the adipogenesis of BMMSCs by activating the GPR120-integrin α Vβ 3-P38-ERK1/2 signalling 
pathway. These findings indicate that GPR120, the G-protein-coupled fatty acid receptor expressed in 
BMMSCs, could have a bi-potential effect in modulating the osteogenesis and adipogenesis of BMMSCs 
in a ligand dose-dependent manner and help us understand more about the relationship between fatty 
acid and bone metabolism.
Furthermore, the in vivo administration of high doses of TUG-891 rescued oestrogen-deficient bone 
loss, supporting the osteo-inductive effect of GPR120 on BMMSCs. However, there was no obvious effect 
of low doses. The cause may be two-fold. First, the concentrations of TUG-891 (0.1 and 1 μ mol/kg) were 
too low to markedly impact the bone micro architecture and bone mass in vivo. Second, the process and 
mechanisms of bone remodelling in vivo were too complicated, and there might be some paracrine fac-
tors that also regulate BMMSCs. Thus, TUG-891 alone at low concentrations did not exhibit a significant 
effect on bone metabolism. One thing need to mention is that although TUG-891 was showed to be a 
selective and potent agonist of GPR120, it still has a chance to activate GPR40, and also other receptors/
pathways which we have no idea yet. Therefore, future work will keep focusing on the underling effect 
of TUG-891 and its potent mechanism in bone-related cells such as BMMSCs, osteoblast and osteoclast.
In conclusion, using both in vivo and in vitro data, we demonstrated that high concentrations of the 
selective GPR120 agonist TUG-891 played a positive role in protecting against bone loss in ovariect-
omized mice and improved osteogenesis via the GPR120-integrin α 1β 1, α 2β 1-Ras-ERK1/2 signalling 
Figure 8. GPR120 increases the bone formation rate (BFR) of ovariectomized mice. Fluorochrome 
double labelling was performed by intramuscular injection of tetracycline hydrochloride and calcein 
administered 12 and 2 days before sacrifice. In all of the groups, the fresh osteoids were labelled with 
tetracycline hydrochloride and calcein. (A) Fluorochrome double labelling of each group. (B) Quantification 
of the bone formation rate between each group. Groups: a: Sham; b: OVX; c: OVX + TUG-891 (0.1 mg/
kg); d: OVX + TUG-891 (1 mg/kg); e: OVX + TUG-891 (5 mg/kg); f: OVX + TUG-891 (10 mg/kg); g: 
OVX + TUG-891 (30 mg/kg); h: OVX + TUG-891 (50 mg/kg). *P < 0.05 and **P < 0.01 compared with the 
sham group. #P < 0.05 and ##P < 0.01 compared with the OVX group.
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pathway. Low concentrations of TUG-891 induced the adipogenesis of BMMSCs in vitro via GPR120- 
integrin α Vβ 3-p38 and the subsequent inhibition of ERK1/2. Our findings established another link 
between fat and bone and elucidated the role and function of FFAs in bone metabolism through the 
receptor GPR120. Above all, as we showed in this study, GPR120 mediates bi-potential differentiation 
potency of BMMSCs by ligand dosage-dependent manner, which indicates a potential clinical targets and 
applications. The activation by high dosages of TUG-891 exerts osteogenic effect of BMMSCs, which can 
be further researched for the treatment of skeletal diseases. Low dosages of TUG-891 markedly induced 
adipogenesis of BMMSCs, which indicates that GPR120 is metabolically protective, because adipogenesis 
in human species protects against insulin resistance and diabetes in the context of obesity. In this regard 
both sides of the bimodal effect of GPR120 may have a protective effect in the context of obesity and 
will undoubtedly help us to better understand skeletal diseases, such as osteoporosis over the next few 
decades.
Until now, GPR120 has been suggested to be a potential candidate and target to treat type 2 diabetes 
and obesity-induced inflammatory disease52,53. In the prevalence of age- and metabolic-related disorders, 
our findings highlighted the essential role of GPR120 in mediating the bi-potential differentiation of 
BMMSCs and the ability of a GPR120 agonist to protect against bone loss in vivo. These findings inspire 
us to consider that GPR120 and its agonist may be a new molecular target and remedy, respectively, to 
combat osteoporosis for the foreseeable future.
Materials and Methods
Animals. Healthy female C57BL/6 mice, weighing 20.7 ± 1.20 g, were obtained from the Experimental 
Animal Center, Fourth Military Medical University Xi’an, China, and were acclimated to laboratory con-
ditions for 1 week before commencement of the experiment.
For the OVX experiments, 12-week-old mice were bilaterally ovariectomized. The ovaries of 
sham-operated mice were left intact. The mice were randomly divided into distinct groups: (n = 9 per 
group; sham-operated/control vehicle; OVX/control vehicle; OVX/TUG-891). Injection of the bone mar-
row cavity was started after a 48-h recovery period. Three times per week mice received 5 μ L of both 
DMSO as the control vehicle or TUG-891 at a concentration of 0.1, 1, 5, 10, 30 or 50 μ mol/kg for the 
different groups for 10 weeks. The left femurs of the mice were collected, and the adherent tissue was 
discarded.
Ethics Statement. All experimental procedures in animals were approved by the Ethics in Animal 
Research Committee of the Fourth Military Medical University (permission code 20110405-5). All meth-
ods were carried out in “accordance” with the approved guidelines.
Cell culture. BMMSCs were isolated from C57BL/6 mice as previously described54, and cells were 
characterized using mesenchymal stem cell minimal criteria55. Briefly, the bone marrow was flushed 
out of the long bones of mice and plated as a cell suspension (0.5 × 106 cells cm−2) in α -MEM supple-
mented with 15% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 μ g/ml streptomycin. Culture dishes 
were incubated at 37 °C in a humidified atmosphere of 95% air and 5% CO2. The culture medium was 
replaced every other day. Homogeneous BMMSCs were obtained for three generations. For osteogenic 
induction, BMMSCs were cultured at 1 × 105 cells/cm2 in DMEM expansion medium supplemented with 
osteogenic supplements, 1 μ M dexamethasone, 10 mM β -glycerophosphate, and 50 μ g/ml ascorbic acid in 
the presence or absence of TUG-891 from a concentration of 0.1 to 100 μ M for 14 days. For adipogenic 
induction, cells were cultured at 1 × 105 cells/cm2 in an adipogenic hormonal cocktail expansion medium 
supplemented with 10 μ M dexamethasone, 5 μ g/ml insulin, and 0.5 mM 3-isobutyl-1-methylxantine in 
the presence or absence of TUG-891 from a concentration of 0.1 to 5 μ M for 3 days. The medium was 
replaced every other day.
Transfection of Lentiviral Vectors with shRNA for GPR120. The pGMLV-GFP-vshRNA-GPR120 
shRNAi vector was constructed (pGMLV; Shanghai Genomeditech Co. Ltd). In the present study, 
we constructed 3 vshRNA-GPR120 lentiviral vectors (pGMLV-GFP-shRNA-GPR120) to silence the 
expression of GPR120 in murine BMMSCs (BMMSCs-vshRNA-GPR120). The three shRNA-targeting 
sequences for GPR120 were as follows: #1, 5′ -GCACCCACTTCCCTTTCTTCT-3′ ; #2, 5′ -GCTCTTCTA 
CGTGATGACAAT-3′ ; and #3, 5′ -GGACCAGGAAATTCCGATTTG-3′ . Stably transfected clones 
were characterized by reverse transcription-polymerase chain reaction (RT-PCR), western blotting and 
immunostaining.
Alkaline phosphatase (ALP) staining and activity assay. Cells were washed twice with 
phosphate-buffered saline (PBS), fixed with 10% formalin in PBS for 30 s, rinsed with deionized water, 
and stained with a BCIP/NBT alkaline phosphatase colour development kit under protection from direct 
light. To measure ALP activity, the cells were lysed with RIPA buffer. The samples were then centrifuged 
at 10,000 × g for 5 min, and ALP activity was measured in clear supernatants using an ALP activity assay 
kit. The total protein concentrations were determined by the Bradford protein assay. ALP activity was 
normalized to the total protein concentrations.
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Alizarin red staining for the mineralized matrix. Cells were fixed in ice-cold 10% formalin for 
20 min and stained with 40 mM alizarin red S (pH 4.4, Sigma Chemical) for 45 min at room temperature. 
To estimate matrix calcification, the stain was solubilized with 10% cetylpyridinum chloride by shaking 
for 15 min. The absorbance of the released alizarin red S was measured at 562 nm56.
Oil red O staining and quantification of adipocytes. Adipocyte fat droplets were observed by the 
oil red O staining method with minor modifications57. Cell monolayers were fixed in 4% paraformalde-
hyde, washed with water, and stained with 0.6% (w/v) oil red O containing 60% isopropanol for 15 min at 
room temperature. For quantification of adipocytes, cell monolayers were washed extensively with water 
to remove unbound dye, and 1 ml of isopropyl alcohol was added to the culture dish. Adipocytes were 
quantified by counting the red pixels in five random microscopic images per well using Adobe Photoshop 
software. The values were expressed as a percentage of the total pixels in each microscopic image58.
RNA purification and quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA 
was purified from cells using Trizol® (Invitrogen). RT-PCR was performed, and the results were analysed 
as previously described59. All of the RT-PCR experiments were performed in triplicate, and the primer 
sequences were as follows: Alp (Fwd) GAGATGGTATGGGCGTCTC, (Rvs) GTTGGTGTTGTACGTC 
TTGGA; Runx2 (Fwd) GCACAAACATGGCCAGATTCA, (Rvs) AAGCCATGGTGCCCGTTAG; Ocn  
(Fwd) GACAAGTCCCACACAGCAACT, (Rvs) GGACATGAAGGCTTTGTCAGA; Fabp4 (Fwd) TGGG 
AACCTGGAAGCTTGTCTC, (Rvs) GAATTCCACGCCCAGTTTGA; PPARG (Fwd) GGAGCCTAAG 
TTTGAGTTTGCTGTG, (Rvs) TGCAGCAGGTTGTCTTGGATG; β-actin (Fwd) CTGGCACCACA 
CCTTCTACA, (Rvs) GGTACGACCAGAGGCATACA.
Western blotting. Cells were lysed in lysis buffer (50 mM Tris–HCl, pH 7.4, containing 150 mM 
NaCl, 1% Nonidet™ P-40, 0.1% SDS, 10 mg/ml leupeptin, 10 mg/ml pepstatin A, and 10 mg/ml apro-
tinin) on ice for 30 min. For western blot analysis, 10 μ g of total protein was resolved by 10% SDS-PAGE, 
and the proteins were transferred onto a PVDF membrane. Anti-GPR120 (1:1000), anti-ERK1/2 (1:5000), 
anti-p-ERK1/2 (1:2000), anti-Akt (1:2000), anti-PI3K (1:5000), anti-JNK (1:2000), anti-p38 (1:2000), 
anti-pp38 (1:2000), anti-integrin α 1 (1:2000), anti-integrin α 2 (1:2000), anti-integrin α V (1:2000), 
anti-integrin β 1 (1:2000), anti-integrin β 3 (1:2000), anti-Ras (1:1000), and anti-Ras-GRF1 (1:1000) 
antibodies were used for immunoblotting. α -Tubulin was used as a loading control. The horseradish 
peroxidase-conjugated secondary antibody was used at a 1:5000 dilution. Images were analysed using 
Scion Image software.
Immunostaining. Cells were fixed in 4% paraformaldehyde for 15 min, permeabilized with methanol 
for 10 min, and incubated with primary antibodies anti-GPR120 (1:100) antibodies overnight. On the 
following day, the cells were incubated with a DyLight® 594 secondary antibody (Abcam) for 1 h. After 
staining nuclei with DAPI (0.5 μ g/ml) for 5 min, the cells were analysed under a FV1000 model confocal 
microscope (Olympus, Tokyo, Japan).
Assessment of bone micro-architecture and bone mass by micro-computed tomography. 
The distal femurs were scanned using explore Locus SP Pre-Clinical Specimen micro-CT (GE Healthcare, 
USA) with an 8-mm resolution, a 50-kV tube voltage and a 0.1-mA tube current. The reconstruction 
and 3D quantitative analyses were determined using software provided by a desktop micro-CT system 
(GE Healthcare, USA). Similar settings for scans and analyses were used for all of the samples. In the 
femur, the scanning regions were confined to the distal metaphysis, extending proximally 2.0 mm from 
the proximal tip of the primary spongiosa. The trabecular bone region from the vertebral body was out-
lined for each micro-CT slice, excluding both the cranial and caudal endplate regions. The following 3D 
indices in the defined region of interest (ROI) were analysed: bone mineral density (BMD), connectivity 
density (Conn.D), structure model index (SMI), trabecular number (Tb.N), trabecular thickness (Tb.Th), 
trabecular separation (Tb.Sp) and relative bone volume over the total volume (BV/TV, %). The operator 
who conducted the scan analysis was blinded to the procedure associated with the specimens.
Histological examination by Van Gieson (VG) staining. The left femur of all of the mice were 
collected and fixed in 4% paraformaldehyde for 48 h. After dehydration and embedding, the distal femur 
was embedded in polymethyl-methacrylate (PMMA) and processed into 240-mm-thick sections in the 
coronal plane using a rotation microtome. Subsequently, all of the sections were hand-grounded to a 
thickness of 20 mm for VG staining, which was used for staining collagen fibre59.
Fluorochrome double labeling. Fluorochrome labelling of the bones was performed by intramuscu-
lar injection of tetracycline hydrochloride (20 mg/kg) and calcein (5 mg/kg) administered 12 and 2 days 
before sacrifice, respectively. Next, the left femurs were fixed, dehydrated, embedded and sliced (10 μ m). 
At the point of intersection, the distance between the middle of the two fluorescein labels was measured 
by a magnification of × 200. The BFR was then calculated by dividing the distance between the two labels 
by the inter-labelling period in days.
All methods were carried out in “accordance” with the approved guidelines.
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Statistical analysis. Data were expressed as means ± S.D. of multiple repeats of the same experiment 
(n = 3). The data for these measurements were analyzed by one-way analysis of variance (ANOVA) with 
subsequent post hoc multiple comparisons by Dunnett’s test. Statistically significant values were defined 
as P < 0.05.
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